The National Institute for Health and Care excellence have drafted guidelines for the treatment of recurrent ovarian cancer, which recommend two therapies for NHS use but have also rejected a further three drugs.
Spain’s Zeltia has announced that after a portfolio review, its PharmaMar unit has decided to end the development of one of their marine-based cancer drugs, Irvalec, and instead focus on advancing five drugs, including the already-approved Yondelis. Zeltia is a world-leading biopharmaceutical organisation, specialising in the development of marine based drugs for use in oncology
